Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 8

From bench to bedside: use of human adipose-derived stem cells

Authors Feisst V, Meidinger S, Locke M

Received 27 May 2015

Accepted for publication 31 August 2015

Published 2 November 2015 Volume 2015:8 Pages 149—162

DOI https://doi.org/10.2147/SCCAA.S64373

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Zhifang Qiu

Peer reviewer comments 2

Editor who approved publication: Dr Bernard Binetruy


Vaughan Feisst,1 Sarah Meidinger,1 Michelle B Locke2

1Dunbar Laboratory, School of Biological Sciences, 2Department of Surgery, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand


Abstract: Since the discovery of adipose-derived stem cells (ASC) in human adipose tissue nearly 15 years ago, significant advances have been made in progressing this promising cell therapy tool from the laboratory bench to bedside usage. Standardization of nomenclature around the different cell types used is finally being adopted, which facilitates comparison of results between research groups. In vitro studies have assessed the ability of ASC to undergo mesenchymal differentiation as well as differentiation along alternate lineages (transdifferentiation). Recently, focus has shifted to the immune modulatory and paracrine effects of transplanted ASC, with growing interest in the ASC secretome as a source of clinical effect. Bedside use of ASC is advancing alongside basic research. An increasing number of safety-focused Phase I and Phase IIb trials have been published without identifying any significant risks or adverse events in the short term. Phase III trials to assess efficacy are currently underway. In many countries, regulatory frameworks are being developed to monitor their use and assure their safety. As many trials rely on ASC injected at a distant site from the area of clinical need, strategies to improve the homing and efficacy of transplanted cells are also being explored. This review highlights each of these aspects of the bench-to-bedside use of ASC and summarizes their clinical utility across a variety of medical specialties.

Keywords: standardization, bystander effect, stromal cells, mesenchymal stem cells, stromal vascular fraction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]